1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Tokuyama Corporation

Tokuyama Corporation

TKYMY
Tokuyama CorporationUS flagOther OTC
14.00
USD
- -
- -
2.01BMarket Cap
Tokuyama Corporation
TKYMY
(Other OTC)

Recent

price

14.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
2,081.97
2,028.9
1,858.32
2,064.69
2,170.92
2,207.22
2,149.8
2,214.35
2,335.86
2,275.55
2,163.85
2,041.54
2,444.65
2,376.65
2,384.27
2,428.77
1,222.43
Revenue per Share
70.16
67.19
-272.43
73.42
-469.63
-722.74
374.93
141.59
246.63
143.52
175.55
194.54
65.07
123.36
162.54
154.32
80.09
Basic EPS, GAAP
74.6
-123.41
-121.42
30.17
-12.2
113.3
23.86
333.23
156.6
235.1
139.63
-41
-303.79
168.43
206.89
152.02
- -
Free Cash Flow per Basic Share
14.99
14.74
7.52
14.95
7.5
0.01
- -
10.45
22.46
29.98
34.78
34.98
35
35.01
47.53
55.05
- -
Dividend per Share
1,323.74
1,375.91
1,095.86
1,154.13
666.5
-56.22
593.04
724.21
949
1,063.03
1,197.33
1,323.83
1,354.06
1,441.44
1,556.42
1,655.65
1,499.91
Book Value per Share
1,711.11
1,774.35
1,551.39
1,626.29
1,147.39
386.74
942.91
961.94
1,162.32
1,286.96
1,455.26
1,599.67
1,654.85
1,782.42
1,873.97
1,630.33
1,823.27
Tangible Book Value per Share
139
139
139
139
139
139
139
139
139
139
140
144
144
144
144
144
144
Basic Weighted Avg Shares
289,786
282,381
258,632
287,330
302,085
307,115
299,106
308,061
324,661
316,096
302,407
293,830
351,790
341,990
343,073
349,476
175,885
Sales/Revenue/Turnover
6.95
4.86
2.62
7.05
6.47
7.51
12.88
13.4
10.86
10.85
9.96
8.35
4.08
7.5
8.74
9.55
9.7
Operating Margin (%)
31,256
28,379
23,099
16,642
18,845
20,084
14,215
13,985
15,093
16,122
17,003
19,716
20,773
17,690
19,755
22,470
- -
Depreciation Expense
9,765
9,351
-37,916
10,218
-65,349
-100,563
52,165
19,698
34,279
19,937
24,534
28,000
9,364
17,751
23,388
22,205
11,523
Net Income, GAAP
34.27
32.95
- -
18.9
- -
- -
- -
22.84
7.86
24.8
18.21
- -
35.09
32.66
25.67
38.19
31.25
Effective Tax Rate (%)
3.37
3.31
-14.66
3.56
-21.63
-32.74
17.44
6.39
10.56
6.31
8.11
9.53
2.66
5.19
6.82
6.35
6.55
Profit Margin (%)
121,523
112,026
70,488
92,326
126,677
130,566
167,508
97,999
109,688
108,608
116,452
121,613
165,445
113,841
143,292
90,577
138,357
Working Capital
98,702
123,714
152,310
215,231
237,533
208,208
196,742
121,042
111,178
96,283
86,483
86,705
137,352
83,076
99,838
122,866
101,170
LT Debt
247,656
255,459
223,869
236,451
169,444
60,204
135,976
136,591
163,524
180,428
205,260
232,916
241,601
259,946
273,856
297,810
266,398
Total Equity
3.67
2.35
- -
3.68
- -
- -
- -
10.07
11.27
8.65
8.13
- -
2.55
4.58
5.89
4.85
3.13
Return on Invested Capital (%)
3.5
3.06
- -
3.23
- -
- -
- -
6.05
13.68
7.37
9.12
- -
3.16
5.64
7.21
5.97
3.64
Return on Capital (%)
5.41
4.98
-22.04
6.53
-51.59
- -
- -
21.5
29.47
14.26
15.58
15.65
4.86
8.83
10.84
9.61
5.56
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
22,706
- -
8,707
LT Borrowings
78,262
- -
96,507
LT Finance Leases
4,814
- -
4,663
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
72
- -
72
Market Capitalization
195,465
210,440
208,057

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
217,776
- -
222,504
Cash, Cash Equivalents & STI
48,684
- -
65,227
Accounts Receivable, Net
82,745
- -
75,193
Inventories
71,888
- -
73,491
Total Current Liabilities
103,935
- -
84,147
Payables & Accruals
- -
- -
- -
ST Debt
22,706
- -
8,707
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.9%
7.78%
8.75%
Free Cash Flow
152.6%
70.29%
-26.52%
Net Income, GAAP
-9.5%
12.77%
-5.06%
Sales/Revenue/Turnover
1.51%
3.26%
1.87%
Total Cash Common Dividend
- -
11.04%
15.82%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
84,886
81,219
84,150
91,735
341,990
2025
- -
- -
- -
- -
343,073
2026
- -
- -
- -
- -
349,476

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29.91
- -
- -
- -
123.36
2025
- -
- -
- -
- -
162.54
2026
- -
- -
- -
- -
154.32

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
35.01
2025
- -
- -
- -
- -
47.53
2026
- -
- -
- -
- -
55.05
Similar Companies
Saudi Industrial Investment Group (2250.SR)
California Nanotechnologies Corp. (CNO.V)
Isamu Paint Co., Ltd. (4624.T)
Tokai Carbon Co., Ltd. (TKCBF)
Qingdao Gon Technology Co., Ltd. (2768.HK)
Tainwala Chemicals and Plastics (India) Limited (TAINWALCHM.NS)
Business
Tokuyama Corporation Tokuyama Corporation (TKYMY) manufactures and sells basic chemicals, specialty products, cement, and related materials primarily in Japan, with operations extending to Taiwan, China, the United States, and other regions; the company produces caustic soda (liquid and solid forms), propylene oxide, vinyl chloride monomer, polyvinyl chloride resin, soda ash, calcium chloride, high-purity polycrystalline silicon, fumed silica under the REOLOSIL brand, spherical silica products such as EXCELICA and SILIFIL, aluminum nitride powders and ceramics under the SHAPAL brand, boron nitride, high-purity chemicals for electronics including IPA SE and photoresist developers, portland cement varieties, dental materials through Tokuyama Dental Corporation, medical diagnosis systems via A&T Corporation, in vitro diagnostics from MEDICAL&BIOLOGICAL LABORATORIES Co., Ltd., microporous films like Porum and NF Sheet, photochromic materials, hard coating solutions for lenses under the TS-56 Series, APIs and intermediates such as di-tert-butyl dicarbonate and Triazimoch, hydrophobic silica aerogel Airlica for cosmetics, ion exchange membranes through ASTOM Corporation, and waste gypsum recycling products. Founded in 1918 as Nihon Soda Kogyo Co., Ltd. and headquartered at Front Place Akihabara in Tokyo with its registered headquarters and primary factory in Shunan-shi, Yamaguchi Prefecture, Tokuyama operates through segments including chemicals, cement, electronic and advanced materials, life science, and eco business, serving industries such as semiconductors, construction, healthcare, cosmetics, and environmental management. In recent developments, the company completed the acquisition of a newly established entity succeeding JSR Corporation's in vitro diagnostic and in vitro diagnostic materials businesses on October 1, 2025, renaming it Tokuyama Life Science Corporation for consolidation starting in the second half of fiscal 2025; additionally, Tokuyama reported Q2 fiscal 2025 results with increased operating profit from cost improvements despite lower net sales due to vinyl chloride price declines, alongside strong semiconductor-related product performance.

Company News

APIChatGPT

  • defenseworld.net

    Tokuyama (OTCMKTS:TKYMY) versus Stepan (NYSE:SCL) Head to Head Comparison

  • defenseworld.net

    Tokuyama (OTCMKTS:TKYMY) versus Gulf Resources (NASDAQ:GURE) Financial Contrast

  • defenseworld.net

    Head-To-Head Review: Tokuyama (OTCMKTS:TKYMY) vs. Kronos Worldwide (NYSE:KRO)

  • defenseworld.net

    Tokuyama (OTCMKTS:TKYMY) Trading 1.8% Higher – Here’s Why